AUTL — Autolus Therapeutics plc stock price, charts and financials

Latest market price

2.17

+0.05+2.61%

Overview Short InterestFilings

AUTLQT71Autolus Therapeutics plc·NASDAQ

Overview Short InterestFilings

2.17+2.61%

Loading chart...

Screen all →

AUPH-2.33%$15.48 MESO+4.96%$16.73 ZBIO-1.46%$31.96 GHRS-2.07%$29.64 TSHA-0.69%$6.51 STOK-1.46%$32.23 ABCL+31.03%$9.08 VRDN-2.29%$23.05

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	0.16%	Shs Outstand	266.14M	Perf Week	41.61%

Market Cap	561.56M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	0.00%	Shs Float	240.52M	Perf Month	24.85%

Enterprise Value	510.59M	PEG	0.08	EPS next Q	-	Inst Own	-	Short Float	6.30%	Perf Quarter	31.06%

Income	-288.81M	P/S	6.07	EPS this Y	21.11%	Inst Trans	-	Short Ratio	10.73	Perf Half Y	59.85%

Sales	92.59M	P/B	5.16	EPS next Y	24.68%	ROA	-54.80%	Short Interest	15.14M	Perf YTD	6.03%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-128.53%	52W High	2.59 -16.27%	Perf Year	-8.66%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-56.74%	52W Low	1.21 78.81%	Perf 3Y	-32.59%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	133.11% 106.99%	Gross Margin	-11.19%	Volatility	12.64% 7.89%	Perf 5Y	-60.34%

Dividend TTM	-	EV/Sales	5.51	EPS Y/Y TTM	-25.29%	Oper. Margin	-285.90%	ATR (14)	0.14	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	5.28	Sales Y/Y TTM	820.00%	Profit Margin	-311.95%	RSI (14)	73.72	Recom	2.21

Dividend Gr. 3/5Y	-	Current Ratio	5.80	EPS Q/Q	-3.85%	SMA20	32.75%	Beta	2.10	Target Price	8.87

Payout	0.00%	Debt/Eq	0.73	Sales Q/Q	188.89%	SMA50	31.92%	Rel Volume	1.27	Prev Close	2.11

Employees	752	LT Debt/Eq	1.89	Earnings	Aug 11	SMA200	36.86%	Avg Volume	1.60M	Price	2.17

IPO Date	Jun 22, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	-6.73% -0.18%	Net Debt/EBITDA	0.22	Volume	2,033,205	Change	2.61%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Nov-18-24	Upgrade	Goldman Sachs	Neutral → Buy	$7.60
Nov-15-24	Upgrade	Redburn Atlantic	Neutral → Buy
May-20-24	Reiterated	Wells Fargo	Overweight	$8.00
Mar-10-21	Downgrade	Redburn	Buy → Neutral
Mar-09-21	Downgrade	Redburn	Buy → Neutral
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral

Latest News

Aug-03-26

Aug-03-2604:30PM

Top stock movements in today's session.ChartMill

04:05PM

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026globenewswire.com

07:13AM

Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisorsglobenewswire.com

Jul-22-26

Jul-22-2610:51AM

Autolus Therapeutics: Navigating A Bumpy 2026seekingalpha.com

Jul-08-26

Jul-08-2609:35AM

3 Cancer Stocks to Watch as Oncology Innovation Accelerateszacks.com

Jul-01-26

Jul-01-2604:05PM

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Company

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 9/30/2018
Total Revenue	92	76	10	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	103	97	141	—	—	—	—	—	—
Gross Profit	-10	-21	-131	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	142	132	0	—	—	—	—	—	—
Research and Development	112	129	158	—	—	—	—	—	—
Other Operating Expense	0	-1	-47	—	—	—	—	—	—
Operating Income	-265	-281	-241	—	—	—	—	—	—
Interest Expense	45	37	9	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	22	21	32	—	—	—	—	—	—
Net Income Before Taxes	-289	-297	-219	—	—	—	—	—	—
Income Taxes	1	-9	2	—	—	—	—	—	—
Consolidated Net Income	-289	-288	-221	—	—	—	—	—	—
Net Income From Continuing Operations	-289	-288	-221	—	—	—	—	—	—
Net Income	-289	-288	-221	—	—	—	—	—	—
EPS (Recurring)	-1.09	-1.08	-0.87	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.09	-1.08	-0.87	—	—	—	—	—	—
EPS (Diluted)	-1.09	-1.08	-0.87	—	—	—	—	—	—
EBITDA	-231	-250	-233	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	6.26	6.97	59.93	—	—	—	—	—	—
Gross Margin	-10.87	-27.63	-1,310.00	—	—	—	—	—	—
Operating Margin	-288.04	-369.74	-2,410.00	—	—	—	—	—	—
Net Margin	-314.13	-378.95	-2,210.00	—	—	—	—	—	—
Shares Outstanding	266	266	255	—	—	—	—	—	—
Market Capitalization	576	529	599	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.